Journal article
Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study
Abstract
PURPOSE: Ibrutinib reduces mortality in chronic lymphocytic leukemia (CLL). It increases the risk of atrial fibrillation (AF) and bleeding and there are concerns about heart failure (HF) and central nervous system ischemic events. The magnitude of these risks remains poorly quantified.
METHODS: Using linked administrative databases, we conducted a population-based cohort study of Ontario patients who were treated for CLL diagnosed between 2007 …
Authors
Abdel-Qadir H; Sabrie N; Leong D; Pang A; Austin PC; Prica A; Nanthakumar K; Calvillo-Argüelles O; Lee DS; Thavendiranathan P
Journal
Journal of Clinical Oncology, Vol. 39, No. 31, pp. 3453–3462
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
November 1, 2021
DOI
10.1200/jco.21.00693
ISSN
0732-183X